MX2011013069A - Composiciones solidas que comprenden acido 5-aminolevulinico. - Google Patents

Composiciones solidas que comprenden acido 5-aminolevulinico.

Info

Publication number
MX2011013069A
MX2011013069A MX2011013069A MX2011013069A MX2011013069A MX 2011013069 A MX2011013069 A MX 2011013069A MX 2011013069 A MX2011013069 A MX 2011013069A MX 2011013069 A MX2011013069 A MX 2011013069A MX 2011013069 A MX2011013069 A MX 2011013069A
Authority
MX
Mexico
Prior art keywords
aminolevulinic acid
cancerous
solid compositions
solid
pharmaceutical products
Prior art date
Application number
MX2011013069A
Other languages
English (en)
Spanish (es)
Inventor
Jo Klaveness
Jon Erik Braenden
Aslak Godal
Oddveig Sallaeg Helland
Gry Stensrud
Bjorn Klem
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42628133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011013069(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Photocure Asa filed Critical Photocure Asa
Publication of MX2011013069A publication Critical patent/MX2011013069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011013069A 2009-06-11 2010-06-11 Composiciones solidas que comprenden acido 5-aminolevulinico. MX2011013069A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09251538 2009-06-11
PCT/EP2010/003531 WO2010142456A1 (en) 2009-06-11 2010-06-11 Solid compositions comprising 5-aminolevulinic acid

Publications (1)

Publication Number Publication Date
MX2011013069A true MX2011013069A (es) 2012-02-01

Family

ID=42628133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013069A MX2011013069A (es) 2009-06-11 2010-06-11 Composiciones solidas que comprenden acido 5-aminolevulinico.

Country Status (18)

Country Link
US (1) US20120134921A1 (enExample)
EP (1) EP2440188A1 (enExample)
JP (1) JP2012529451A (enExample)
KR (1) KR20140014401A (enExample)
CN (1) CN102802612A (enExample)
AU (1) AU2010257752B2 (enExample)
BR (1) BRPI1011650A2 (enExample)
CA (1) CA2763837A1 (enExample)
CL (1) CL2011003115A1 (enExample)
CO (1) CO6480960A2 (enExample)
CR (1) CR20110649A (enExample)
MX (1) MX2011013069A (enExample)
NZ (1) NZ596946A (enExample)
PE (1) PE20120858A1 (enExample)
RU (1) RU2527328C2 (enExample)
SG (1) SG176687A1 (enExample)
WO (1) WO2010142456A1 (enExample)
ZA (1) ZA201108850B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521251A (ja) 2010-03-01 2013-06-10 フォトキュア エイエスエイ 美容組成物
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
US20140067024A1 (en) 2012-08-30 2014-03-06 Photocure Asa Dual panel photodynamic therapy lamp
GB201221123D0 (en) 2012-11-23 2013-01-09 Photocure As Device for photodynamic treatment
CN105338962A (zh) * 2013-03-12 2016-02-17 应用生物学研究有限公司 用于改善的药物递送的螯合栓剂
EP3181125B1 (en) * 2014-07-31 2025-02-19 Capsugel Belgium NV Capsule formulation
JP6588193B2 (ja) * 2014-07-31 2019-10-09 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル製剤
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
US9956426B2 (en) 2015-02-26 2018-05-01 Amol Punjabi Upconverting nanoparticles
EP3389716B1 (en) * 2015-12-17 2022-03-23 Photocure ASA Method of photodynamic therapy (pdt) for bladder cancer
CN105481946B (zh) * 2015-12-18 2019-05-21 浙江工商大学 5-氨基酮戊酸与3-羟基吡啶-4-酮的缀合物及其制备法和用途
GB201522398D0 (en) 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
US10744212B2 (en) 2016-03-14 2020-08-18 General Electric Company Topical application of nerve labeling dyes for image-guided surgery
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
WO2018195067A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
CN107434753A (zh) * 2017-07-26 2017-12-05 南京大学 5‑氨基乙酰丙酸及其衍生物的泡腾片及其制备方法
US11266619B2 (en) 2017-12-01 2022-03-08 Sbi Pharmaceuticals Co., Ltd. Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
JP2024006280A (ja) * 2022-07-01 2024-01-17 ネオファーマジャパン株式会社 安定性に優れた非水性製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3181062B2 (ja) * 1991-01-31 2001-07-03 帝國製薬株式会社 下部消化管崩壊経口製剤
DE122006000051I1 (de) * 1995-03-10 2007-01-04 Photocure Asa Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie
US6492420B2 (en) * 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
JP4815053B2 (ja) * 1998-08-13 2011-11-16 シーマ・ラブス、インコーポレイテッド 経口投与の固形投与形態物としてのマイクロエマルション
WO2000074720A1 (fr) * 1999-06-09 2000-12-14 Mochida Pharmaceutical Co., Ltd. Systeme de liberation dans les voies digestives inferieures
DE10003620A1 (de) * 2000-01-28 2001-08-02 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US7264629B2 (en) * 2001-11-09 2007-09-04 Qlt, Inc. Photodynamic therapy for the treatment of hair loss
TW577606U (en) * 2001-11-20 2004-02-21 Carry Computer Eng Co Ltd Improved structure of all-in-one silicon disk
DE102005019628A1 (de) * 2005-04-26 2006-11-09 Technische Universität Braunschweig Formulierung zur dermalen Anwendung
GB0609809D0 (en) * 2006-05-17 2006-06-28 Photocure Asa Product
GB0724279D0 (en) * 2007-12-12 2008-01-23 Photocure Asa Use

Also Published As

Publication number Publication date
CO6480960A2 (es) 2012-07-16
US20120134921A1 (en) 2012-05-31
CN102802612A (zh) 2012-11-28
CR20110649A (es) 2012-03-22
WO2010142456A1 (en) 2010-12-16
JP2012529451A (ja) 2012-11-22
RU2527328C2 (ru) 2014-08-27
KR20140014401A (ko) 2014-02-06
AU2010257752A1 (en) 2012-01-12
NZ596946A (en) 2014-07-25
BRPI1011650A2 (pt) 2016-03-22
CA2763837A1 (en) 2010-12-16
AU2010257752B2 (en) 2015-04-09
ZA201108850B (en) 2013-02-27
EP2440188A1 (en) 2012-04-18
RU2011150920A (ru) 2013-07-20
SG176687A1 (en) 2012-01-30
CL2011003115A1 (es) 2012-06-22
PE20120858A1 (es) 2012-08-01

Similar Documents

Publication Publication Date Title
SG176687A1 (en) Solid compositions comprising 5-aminolevulinic acid
UA105229C2 (uk) Фармацевтичний склад
GEP20125599B (en) Proteasome inhibitors
WO2009074811A3 (en) Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2012020131A3 (en) Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
MY165149A (en) Use of binders for manufacturing storage stable formulations
WO2010128050A3 (en) Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds
MY187718A (en) Pharmaceutical formulations
NZ601595A (en) Oral formulations and lipophilic salts of methylnaltrexone
CY1118032T1 (el) Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
HK1208222A1 (en) Modified release formulations for oprozomib
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
WO2011023367A3 (en) Bisphosphonate-prodrugs
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
BR112013000613A2 (pt) composições secas e dispositivos que contêm tais composições secas
WO2011129579A3 (en) Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent
MX346316B (es) Formulacion farmaceutica o nutraceutica.
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2008013860A3 (en) Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
GEP20125680B (en) Carbonic and sulphuric acid salts of 3-(2,2,2-trimethylhydra-zinium) ropionate esters and their use for 3-(2,2,2-rimethyl- hydrazinium) propionate dihydrate preparation
NZ609804A (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Legal Events

Date Code Title Description
FA Abandonment or withdrawal